ClinicalTrials.gg
Active, not recruitingNCT06665256Updated Jun 23, 2026

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

A Phase 2 interventional study of Rapcabtagene autoleucel and Active Comparator Option in Idiopathic Inflammatory Myopathies, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 68 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)

Read the detailed description

This is a Phase 2, randomized, active-controlled study. This study comprises two cohorts:

  • A lead-in cohort enrolling participants to receive rapcabtagene autoleucel
  • A randomized cohort with participants receiving either rapcabtagene autoleucel or a comparator option.

Participants in the comparator arm whose signs and symptoms are not fully controlled may receive rapcabtagene autoleucel treatment once the participant is confirmed to be eligible

After end of study (EOS), participants who received rapcabtagene autoleucel infusion will enter a long-term follow-up (LTFU) period after rapcabtagene autoleucel infusion. This LTFU will be described in a separate study protocol.

02

Conditions studied

  • Idiopathic Inflammatory Myopathies

Keywords

  • Chimeric Antigen Receptor T cells (CAR-T)
  • rapcabtagene autoleucel
  • idiopathic inflammatory myopathies (IIM)
  • dermatomyositis
  • Anti-Synthetase Syndrome
  • Immune-Mediated Necrotizing Myopathy
  • Interstitial Lung Disease
03

In context

Myositis

215 studies on the registry are indexed under Myositis; 100 are open to participants now.

This study's enrollment of 21 is below the median of 30 across 141 interventional studies indexed under Myositis.

Browse Myositis studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Men and women, aged ≥ 18 and ≤75 years, with a diagnosis of probable or definite myositis according to American College of Rheumatology/European League Against Rheumatism 2017 (ACR/EULAR 2017) criteria
  2. Participants who had inadequate response to prior therapy
  3. Diagnosed with active disease such as presence of at least 1 of the following criteria: abnormal enzyme levels assessed as secondary to IIM, or EMG demonstrating active disease, DM skin rash, muscle demonstrating active IIM, or MRI demonstrating active inflammation.
  4. Participant must meet criteria for severe myositis such as presence of active muscle weakness.

Key Exclusion Criteria:

  1. Any condition during Screening that could prevent a complete washout of medications or could otherwise make the participant ineligible for anti-CD19 CAR-T therapy and further participation in the study
  2. at Screening of ≤17 or ≥40 kg/m2
  3. Severe muscle damage at Screening
  4. Inadequate organ function
  5. and/or to any product (including its ingredients) to be given to the participant as per the study protocol
  6. Other inflammatory and non-inflammatory myopathies
  7. Any medical conditions that are not related to IIM that would jeopardize the ability of the participant to tolerate CD19 CAR-T cell therapy

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Rapcabtagene autoleucel

    Single infusion of rapcabtagene autoleucel (YTB323)

    Biological: Rapcabtagene autoleucel

  • Active comparator
    Comparator

    Investigator choice of treatment as per protocol. (Tacrolimus, Mycophenolate mofetil, Cyclophosphamide, or Rituximab)

    Other: Active Comparator Option

Interventions

  • Single infusion of rapcabtagene autoleucel after lymphodepleting therapy with fludarabine (adjusted based on renal impairment) and cyclophosphamide daily for 3 days.

    Also known as: YTB323

  • OtherActive Comparator Option

    Investigator choice of treatment as per protocol

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving moderate- to-major improvement in Total Improvement Score (TIS) at Week 52

    The percentage of participants with a TIS of at least 40 at the 52nd week after the start of the study, corresponding to moderate-to-major improvement.

    Time frame: Week 52

Secondary outcomes

  1. Adjusted annual cumulative glucocorticoid dose up to Week 52

    The total amount of glucocorticoids administered over the course of a year measured up to the 52nd week of treatment.

    Time frame: Week 52

  2. Change from baseline in percent predicted Forced Vital Capacity (FVC%) at Week 52

    The difference in the percentage of the predicted Forced Vital Capacity (FVC) from the start of the study to the 52nd week.

    Time frame: Baseline, Week 52

  3. Proportion of participants achieving major improvement in TIS at Week 52

    The percentage of participants with a TIS of at least 60 at the 52nd week after the start of the study, corresponding to at least major improvement.

    Time frame: Week 52

  4. Change from baseline in Patient-Reported-Outcome Measurement Information System (PROMIS)-Fatigue 7a at Week 52

    The difference in the fatigue levels reported by participants from the start of the study to the 52nd week.

    Time frame: Baseline, Week 52

07

Study locations

68 sites
  • University Of Alabama
    Birmingham, Alabama 35294, United States
  • FL Medical Clinic Orlando Health
    Zephyrhills, Florida 33542, United States
  • Augusta University Georgia
    Augusta, Georgia 30912, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University Of Iowa
    Iowa City, Iowa 52242, United States
  • Duke Clinical Research Institute
    Durham, North Carolina 27710, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15261, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • LDS Hospital
    Salt Lake City, Utah 84143, United States
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
  • Novartis Investigative Site
    Barretos, São Paulo 14784 400, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 01232-010, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 01308-050, Brazil
  • Novartis Investigative Site
    Brest, 29200, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Lyon, 69003, France
  • Novartis Investigative Site
    Marseille, 13885, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Rennes, 35033, France
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50937, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Nuremberg, 90419, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Haifa, 3109601, Israel
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    Monza, MB 20900, Italy
  • Novartis Investigative Site
    Milan, MI 20122, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Verona, VR 37134, Italy
  • Novartis Investigative Site
    Sapporo, Hokkaido 060-8648, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 236-0004, Japan
  • Novartis Investigative Site
    Sendai, Miyagi 9808574, Japan
  • Novartis Investigative Site
    Suita, Osaka 565-0871, Japan
  • Novartis Investigative Site
    Izumo, Shimane 6938501, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 113-8603, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 1138519, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 1608582, Japan
  • Novartis Investigative Site
    Fukuoka, 8128582, Japan
  • Novartis Investigative Site
    Ishikawa, 9208641, Japan
  • Novartis Investigative Site
    Kyoto, 6068507, Japan
  • Novartis Investigative Site
    Amsterdam, North Holland 1105 AZ, Netherlands
  • Novartis Investigative Site
    Riyadh, 11211, Saudi Arabia
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Singapore, S308433, Singapore
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
  • Novartis Investigative Site
    Santander, Cantabria 39008, Spain
  • Novartis Investigative Site
    Pamplona, Navarre 31008, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Córdoba, 14004, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Málaga, 29010, Spain
  • Novartis Investigative Site
    Salamanca, 37007, Spain
  • Novartis Investigative Site
    Geneva, 1211, Switzerland
  • Novartis Investigative Site
    Kaohsiung City, 83301, Taiwan
  • Novartis Investigative Site
    Taichung, 407219, Taiwan
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Sheffield, South Yorkshire S10 2JF, United Kingdom
  • Novartis Investigative Site
    London, NW1 2BU, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Mar 2029, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Oct 30, 2024
StartActual
Dec 17, 2024
Primary completionEst.
Mar 9, 2029
CompletionEst.
Nov 29, 2032
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06665256
Responsible party
Sponsor
First posted
Oct 30, 2024
Start date
Dec 17, 2024
Primary completion
Mar 9, 2029 (estimated)
Completion
Nov 29, 2032 (estimated)
Last update
Jun 23, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rapcabtagene autoleucel

Start the discussion